Ritter Pharmaceuticals Inc (RTTR): Knoll Capital Management Reports New Position

Fred Knoll‘s Knoll Capital Management reported acquiring 526,903 common shares of Ritter Pharmaceuticals Inc (NASDAQ:RTTR) via a 13G filing recently filed with the US Securities and Exchange Commission. The position represents a new addition to Knoll Capital Management’s portfolio, and the stake accounts for 6.14% of the company’s outstanding stock.

Ritter Pharmaceuticals, is a pharmaceutical company that works on developing therapeutics for treating gastrointestinal disorders. Since the beginning of the year, the company’s stock has gained 4.12%. In its last financial report, for the second quarter, Ritter Pharmaceuticals’ disclosed a net loss of $4.1 million or $0.48 per share, which compares to a loss of $2.3 million or $4.18 per share for the corresponding quarter a year earlier. The company did not generate any revenue during the period.

pharmacist, medical, retail, worker, team, young, staff, lab, chemistry, business, drug, chemist, adult, teamwork, drugstore, service,

wavebreakmedia/Shutterstock.com

Among 749 hedge funds from our database, three were bullish on Ritter Pharmaceuticals (NASDAQ:RTTR) at the end of June, same as in the earlier quarter. Those smart money managers were Kevin Kotler‘s Broadfin Capital, which held $1.18 million worth of Ritter Pharmaceuticals’ shares, Julian and Felix Baker’s Baker Bros. Advisors, which owned a position worth $612,000, and Adam Usdan’s Trellus Management Company with a $28,000 worth a position.

Follow Qualigen Therapeutics Inc. (NASDAQ:QLGN)

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Knoll Capital Management 0 526,903 0 526,903 526,903 6.14%
Fred Knoll 0 526,903 0 526,903 526,903 6.14%
Gakasa Holdings 0 526,903 0 526,903 526,903 6.14%

Follow Fred Knoll's Knoll Capital Management

Page 1 of 7 – SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
SCHEDULE 13G*
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2
(Amendment No. __)
Ritter Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, $0.001 par value per share
(Title of Class of Securities)

767836109

(CUSIP Number)

September
21, 2016

(Date of Event Which Requires Filing of the Statement)

Check the appropriate box to designate
the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)

*The remainder of this
cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover
page.

The information required
on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes)

Page 1 of 7

Follow Qualigen Therapeutics Inc. (NASDAQ:QLGN)

Page 2 of 7 – SEC Filing

Cusip No. 767836109 13G Page 2 of 7 Pages

1.

NAME OF REPORTING PERSONS

Knoll Capital Management, LP

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)

(a)     

(b)     

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5.

SOLE VOTING POWER

0

6.

SHARED VOTING POWER

 

526,903

7.

SOLE DISPOSITIVE POWER

0

8.

SHARED DISPOSITIVE POWER

526,903

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

526,903

10.

CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES

CERTAIN SHARES

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.14%

12.

TYPE OF REPORTING PERSON

PN

Page 2 of 7

Follow Qualigen Therapeutics Inc. (NASDAQ:QLGN)

Page 3 of 7 – SEC Filing

Cusip No. 767836109 13G Page 3 of 7 Pages

1.

NAME OF REPORTING PERSONS

Fred Knoll

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)

(a)     

(b)     

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

USA

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5.

SOLE VOTING POWER

0

6.

SHARED VOTING POWER

 

526,903

7.

SOLE DISPOSITIVE POWER

0

8.

SHARED DISPOSITIVE POWER

526,903

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

526,903

10.

CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES

CERTAIN SHARES

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.14%

12.

TYPE OF REPORTING PERSON

IN

Page 3 of 7

Follow Qualigen Therapeutics Inc. (NASDAQ:QLGN)

Page 4 of 7 – SEC Filing

Cusip No. 767836109 13G Page
4 of 7 Pages

1.

NAME OF REPORTING PERSONS

Gakasa Holdings, LLC

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)

(a)     

(b)     

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

Florida

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5.

SOLE VOTING POWER

0

6.

SHARED VOTING POWER

 

526,903

7.

SOLE DISPOSITIVE POWER

0

8.

SHARED DISPOSITIVE POWER

526,903

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

526,903

10.

CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES

CERTAIN SHARES

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.14%

12.

TYPE OF REPORTING PERSON

LLC

Page 4 of 7

Follow Qualigen Therapeutics Inc. (NASDAQ:QLGN)

Page 5 of 7 – SEC Filing

 

Cusip No. 767836109 13G Page
5 of 7 Pages

 

Item 1(a). Name of Issuer:

 

Ritter Pharmaceuticals, Inc. (the “Issuer”)

 

Item 1(b). Address of Issuer’s Principal Executive Offices:

 

1880 Century Park East, Suite 1000

Los Angeles, CA 90067

 

Item 2(a). Name of Persons Filing:

 

Knoll Capital Management LP (“KCMLP”)

Fred Knoll (“Knoll”)

Gakasa Holdings, LLC (“Gakasa”)

Item 2(b). Address of Principal Business Office or, if none,
Residence:

 

The principle business address for each of KCMLP, Knoll and
Gakasa is 5 East 44th Street, Suite 12, New York, NY 10017

Item 2(c). Citizenship:

KCMLP is a limited partnership formed and existing under the
laws of the State of Delaware.

Knoll is a citizen of the United States.

Gakasa is an LLC organized in state of Florida

 

Item 2(d). Title of Class of Securities:

 

This statement on Schedule 13G is being filed with respect to
Common Stock, $0.001 par value per share (the “Common Stock”) of the issuer.

 

Item 2(e). CUSIP Number:
767836109
Item 3. If this statement is filed pursuant to Rules 13d-1(b),
or 13d-2(b) or (c), check whether the person filing is a:
Not applicable
(a) [__] Broker or dealer registered under Section 15 of the Act (15 U.S.C 78o);
(b) [__] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C 78c);
(c) [__] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C 78c);
(d) [__] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e) [__] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
(f) [__] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g) [__] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h) [__] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) [__] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act
(15 U.S.C. 80a-3);
(j) [__] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
(k) [__] Group, in accordance with § 240.13d-1(b)(1)(ii)(K).
Page 5 of 7

Follow Qualigen Therapeutics Inc. (NASDAQ:QLGN)

Page 6 of 7 – SEC Filing

Cusip No. 767836109 13G Page 6 of 7 Pages

If filing as a non-U.S.
institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: _________________

Item 4. Ownership:

Provide the following information regarding
the aggregate number and percentage of class of securities of the issuer identified in Item 1.

(a)       Amount
beneficially owned:

As of this filing:

Gakasa beneficially
owns 526,903 Shares of the Issuer’s Common Stock.

Each of KCMLP and Knoll
beneficially own 526,903 Shares of the Issuer’s Common Stock. KCMLP is the investment manager of Gakasa, and Knoll is the
President of KCMLP.

(b)       Percent of Class:

The percentage set
forth in this Schedule 13G are based upon the total number of shares of the Issuer’s common stock outstanding of 8,584,661
shares as of May 6, 2016, as set forth in the Issuer’s March 31st 2016 10Q.

The 8,584,661 shares
of the Issuer’s Common Stock beneficially owned by each of Gakasa, KCMLP and Knoll constitute 6.14% of the Issuer’s
Common Stock outstanding.

(c)       Number
of shares as to which such person has:

(i) sole power to vote or to direct the vote: 0
(ii) shared power to vote or to direct the vote: 526,903

KCMLP, Knoll
and Gakasa share the power to vote or direct the vote of those shares of Common Stock owned by Gakasa.

(iii) sole power to dispose or to direct the disposition of: 0
(iv) shared power to dispose or to direct the disposition of: 526,903

KCMLP, Knoll
and Gakasa share the power to dispose of or direct the disposition of those shares of Common Stock owned by Gakasa.

Item 5. Ownership of Five Percent or Less of a Class:

If this statement is
being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than
5 percent of the class of securities, check the following .

Item 6. Ownership of More than Five Percent on Behalf of Another
Person:

Not Applicable.

Item 7. Identification and Classification of the Subsidiary
which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

Not Applicable.

Page 6 of 7

Follow Qualigen Therapeutics Inc. (NASDAQ:QLGN)

Page 7 of 7 – SEC Filing

Cusip No. 767836109 13G Page 7 of 7 Pages
Item 8. Identification and Classification of Members of the
Group:

Not Applicable.

Item 9. Notice of Dissolution of Group:

 

Not Applicable

Item 10. Certifications:

By Signing below I certify that, to the
best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with
the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect.

 

SIGNATURE

After reasonable inquiry
and to the best of its knowledge and belief, I certify (the undersigned certifies) that the information set forth in this statement
is true, complete and correct.

KNOLL CAPITAL MANAGEMENT, LP

By: /s/ Fred Knoll

Dated: October 5, 2016

Name: Fred Knoll

Title: President

/s/ Fred Knoll

Dated: October 5, 2016 Fred Knoll

 

GAKASA HOLDINGS, LLC

By: Knoll Capital Management, L.P.,

Investment Manager

By: /s/ Fred Knoll

Dated: October 5, 2016

Name: Fred Knoll

Title: President

Page 7 of 7

Follow Qualigen Therapeutics Inc. (NASDAQ:QLGN)